HC Wainwright restated their buy rating on shares of Timber Pharmaceuticals (NYSE:TMBR – Get Rating) in a research note issued to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock. HC Wainwright also issued estimates for Timber Pharmaceuticals’ Q1 2023 earnings at ($1.17) EPS, Q2 2023 earnings […]